Testosterone is under clinical development by Diurnal Group and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Testosterone’s likelihood of approval (LoA) and phase transition for Secondary (Hypogonadotropic) Hypogonadism took place on 13 Oct 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Testosterone Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Testosterone overview

Testosterone (native oral testosterone) is under development for the treatment of men with primary or secondary hypogonadism. The drug candidate is a lipid formulation and is administered orally. It acts by targeting androgen receptor.

Diurnal Group overview

Diurnal Group is clinical stage pharmaceutical company that targets patient needs in chronic endocrine (hormonal) diseases. Its pipeline products include DNL-0200, DNL-0300, DNL-0400 and DNL-0500. The company offers treatment for congenital adrenal hyperplasia (CAH), adrenal insufficiency, hypogonadism and hypothyroidism. It offers various products which include thyroxine (T4) tablets, hydrocortisone tablets, and fludrocortisone tablets. Diurnal Group is headquartered in Cardiff, Wales, the UK.

Quick View Testosterone LOA Data

Report Segments
  • Innovator
Drug Name
  • Testosterone
Administration Pathway
  • Oral
Therapeutic Areas
  • Male Health
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.